Literature DB >> 6165945

Value of five tumor markers (AFP, CEA, hCG, hPL and SP1) in diagnosis and staging of testicular germ cell tumors.

J J Szymendera, J Zborzil, L Sikorowa, J A Kamińska, A Gadek.   

Abstract

Serum levels of AFP, CEA, hCG, hPL and SP1 were measured by specific radioimmunoassays in 111 patients with testicular germ cell tumors. Seminomas, mature teratomas and "pure type" embryonal carcinomas, as well as the latter two types of tumor with seminomatous admixture, do not produce markers unless in advanced stages when they may do so (small amounts of hCP, hPL and SP1). Tumors composed of yolk-sac elements alone or mixed with embryonal carcinoma produce AFP: of syncytiotrophoblastic elements - hCG, hPL or SP1; and teratomas with differentiated structures - CEA. Compound tumors can produce any of the five markers. When present in serum after orchiectomy or lymphadenectomy, the markers are useful both in diagnosis of the tumor elements that metastasized and in staging; whereas their absence does not exclude regional or distant metastases which may contain only marker-negative elements, e.g., due to changes in tumor histology. Measurement of the serum levels of the markers informs about the remaining regional tumor elements or latent metastases and therefore is more useful than immunoperoxidase staining which provides information on the already dissected structures only.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6165945     DOI: 10.1159/000225555

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Tumour markers in testicular cancer.

Authors:  P A Light
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

Review 2.  Testicular germ cell tumours. Current problems of histogenesis and classification.

Authors:  F Kiss; J Juhász
Journal:  Int Urol Nephrol       Date:  1985       Impact factor: 2.370

3.  The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies.

Authors:  H J Staab; T Brümmendorf; A Hornung; F A Anderer; G Kieninger
Journal:  Klin Wochenschr       Date:  1985-02-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.